CBMX - The train is leaving the station! - 500 Beiträge pro Seite

[MultiCash]

You might want to make sure to get on board!

CombiMatrix Launches ElectraSense(TM) Influenza Surveillance System
Monday March 6, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 6, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group has launched the ElectraSense(TM) Influenza Typing System based on CombiMatrix`s propriety electrochemical detection technology and its Influenza A Typing Microarray.

CombiMatrix is prepared to make this system available to domestic and international government agencies that are engaged in monitoring influenza and planning for a potential pandemic. Using this system, government agencies can verify, before disseminating potentially alarming information to the public, whether samples contain a highly pathogenic substrain of H5N1 or one of the several non-lethal substrains of H5N1. The system is designed for research use, surveillance and monitoring applications, use for animal studies, and other applications not requiring FDA registration. CombiMatrix will seek FDA approval for this product.

The ElectraSense platform is a simple, compact, and rugged system for microarray analysis. This portable system eliminates the bulk, complexity, delicate lasers, and fluorescent dyes common with existing technologies.

The CombiMatrix Influenza A Typing Microarray can identify all strains of Influenza A, including the pathogenic H5N1 strain that has a roughly 50% mortality. Recent studies by CombiMatrix and others indicate that there are multiple sub-strains of H5N1. Some of these are highly pathogenic, some less so, and each may exhibit different responses to drugs such as Tamiflu®. CombiMatrix`s system can differentiate highly pathogenic from less-lethal flu strains and identify strains that may be resistant to therapy, by tracking mutations and recombination events in the genetic makeup of the virus. The system functions even as new mutations appear in influenza strains, maximizing the chance that, as new strains emerge, they can always be detected. In addition, this system can detect mixed or multiple infections of influenza of a single bird or human.

"ElectraSense is an inexpensive yet powerful system for detection and analysis of genomic and proteomic materials on CombiMatrix`s CustomArray(TM). We believe the simplicity of the ElectraSense reader and the power of our Influenza microarray make this system well suited for monitoring influenza outbreaks in the field," said Dr. Amit Kumar, President and CEO of CombiMatrix. "The capabilities of this system are expandable to other pathogens, and we expect to broaden the applications of this product."

[nort.]

gute Zusammenfassung

Thread: Acacia Research-(CBMX)-die CombiIMatrix- Vogelgrippe Play & rebounder 2006 ???

[whyso]

A slow train is coming...but its coming for sure

>>>und der Gr.Partner NVAX>>>

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B2A0…

Spätestens nach der kommende Splitt gehts bei beiden richtig zur sache... ich persönliche sitze viel lieber vorger Bequem im Sattel.

Good trades mit CBMX,
Whyso

[nort.]

prepare:

Renowned Microarray and Genomics Expert, Dr. Mansoor Mohammed, Joins CombiMatrix Molecular Diagnostics

Tuesday March 14, 7:00 am ET

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 14, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that renowned microarray and genomics expert Mansoor Mohammed, Ph.D. has joined CombiMatrix Molecular Diagnostics (CMDX) as its Chief Scientific Officer and a member of its Board of Directors.

ADVERTISEMENT
Dr. Mohammed has been at the forefront of research and development in the fields of Comparative Genomic Hybridization (CGH) and microarray technologies for his entire professional career. Between 2001 and 2003 he produced the world`s first commercially viable whole genome BAC array and co-authored one of its seminal clinical applications. A Bacterial Artificial Chromosome array is a highly efficient and accurate means of detecting genetic abnormalities responsible for a variety of human maladies, such as Down Syndrome, autism, and cancer.

Dr. Mohammed later directed the Advanced Technologies and Genomics program at Quest Diagnostics Incorporated, North America`s largest commercial clinical laboratory. He is an internationally renowned scientist, speaker, and author and holds multiple patents in the fields of clinical genomics and microarray technology.

"CGH is a powerful and transformative diagnostic tool that will complement CMDX`s expertise in gene expression profiling," said Dr. Mohammed. "By bringing the two technologies together under one roof we will be able to provide our customers a truly comprehensive `full spectrum genomic analysis.` I am very excited about joining CMDX and I look forward to helping the company develop and commercialize novel, high value gene-based diagnostic products and services that will assist physicians in making better treatment decisions for their patients."

"I am delighted to have someone of Dr. Mohammed`s caliber and profile within the clinical genomics community join the CMDX team," said Matt Watson, CEO of CombiMatrix Molecular Diagnostics. "As our Chief Scientific Officer he will play a critical role in helping CMDX become the country`s premier center of excellence for molecular diagnostics."

ABOUT DR. MOHAMMED

Mansoor Mohammed, Ph.D. was trained as a molecular immunologist/geneticist at the University of Guelph, Ontario, Canada (recently ranked Canada`s top research university) where he earned a double major doctorate, with distinction. He received post-doctoral training in molecular immunology and clinical cytogenetics at the University of California, Los Angeles (UCLA), where he trained and published with several world leading researchers including Drs. Charles Sawyers, M.D. and Eric Vilain, M.D., Ph.D. In 2001, Dr. Mohammed was recruited by Baylor College of Medicine to continue his clinical cytogenetics training, while directing the scientific research and development of a Baylor-sponsored start-up venture called Spectral Genomics, Inc. It was at Spectral that Dr. Mohammed produced the world`s first commercially viable 1 Megabase human BAC array. Later, as Quest Diagnostics` Director of Advanced Technologies, he was honored with an Outstanding Performance Award (2003), the company-wide Medical Innovation Award (2004), and one of a select few Patent Innovation Awards (2005). Dr. Mohammed also serves as an ambassador of the sciences to the Toronto Genome Center of the renowned Toronto Hospital for Sick Kids.

http://biz.yahoo.com/bw/060314/20060314005238.html?.v=1

[nort.]

Putting the `me` in medicine

For all the progress medicine has made is the past 250 years, the profession is still much akin to that of an auto mechanic: a motorist comes in complaining of some problem, and the mechanic knocks, pokes, and listens, trying to figure out what is amiss.

Yet, until the completion of the Human Genome Project, in 2000, physicians relied almost exclusively on the physical manifestation of a condition to tack a diagnosis-a very hit-and-miss proposition.

"If you look at the individuals who present themselves at the clinic, ... only 30 per cent of patient ever leave the clinic even with a diagnostic," said Dr. Mansoor Mohammed, chief scientific officer at Combimatrix Molecular Diagnostics (CMDX), a biotech start-up based in Irvine, California. "Seventy per cent of patients will actually then leave the clinic without a clue as to what the diagnosis is."

Enter "personalized medicine." A technology called array comparative genomic hybridization (CGH), promises -from detecting congenital conditions in newborns to the classification of tumours in older individuals. Mohammed described the potential of array CGH at an emerging technologies event held Monday morning at the Mars Discovery District.

The point of array CGH is to find changes such as deletions or amplifications in a subject`s DNA test sample, which are indicative of cancer risks. It does so by comparing the relative number of copies of a certain chromosome, in the DNA test sequence with the number of copies of the same in a stretch of generic DNA. Drastic differences in the two show up as bright spots of red or green, giving an indication of DNA gains and losses.

The industry leader, Signature Genomics, based in Spokane, Washington, offers an array CGH test to the public for US$1,600 a pop, which can test for anomalies among 126 different genes. Now Mohammed`s company, CMDX is in the process of setting up a new venture, Genomic Portraits Inc., a majority-owned Canadian company that will soon set up shop in the Mars discovery building. It plans to offer the diagnostic test in Toronto as early as July, for about US$1,000, according to Mohammed.

Advances in the manufacturing of the array, the printing the slides, and competition-due to rising demand-are driving down prices. "I would like to see the test come down during the next two to three years to US$600 or US$700," said Mohammed. That price level, he added, will remove more people`s financial constraints for not taking the test.

http://www.thevarsity.ca/media/paper285/news/2006/02/28/Scie…

[whyso]

Renowned Microarray and Genomics Expert, Dr. Mansoor Mohammed, Joins CombiMatrix -
"Molecular Diagnostics "

This market "Molecular Diagnostics " [/B] is worth a staggering 1,2 Billion $ in the USA alone...

[nort.]

[posting]20.684.316 von whyso am 14.03.06 21:03:09[/posting]"As our Chief Scientific Officer he will play a critical role in helping CMDX become the country`s premier center of excellence for molecular diagnostics."

Und das immer noch UNTER 2$

[whyso]

[posting]20.684.402 von nort. am 14.03.06 21:08:29[/posting]Yepp...schlicht & einfach unglaublich



Aber nicht mehr lange könnte man denken

Good trades & steady hands Amigo,
Whyso

[nort.]

schaut Euch mal die Institutionelle-Quote an und vergleicht die buying power

http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…






Institutionelle sind derzeit bei 20%

[whyso]

WATCH THIS SPACE.....



CombiMatrix Granted Key Nanotechnology Patent
Patent Enables Unique Proteomics Technology and Products


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 16, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group was granted a key patent in Europe (EP1185363B1), titled "Self-Assembling Arrays" by the European Patent Office. This European Patent was registered throughout the European Union in Germany, France, Spain, Great Britain, and Italy, and the opposition period has passed. A corresponding U.S. patent is pending in the U.S. Patent and Trademark Office and is moving through the process.
ADVERTISEMENT


The European patent claims both self-assembled arrays and a method for making self-assembled arrays on electrode arrays with self-assembled antibodies. This microarray configuration is especially useful for arraying proteins specifically antibodies. The technology enables products such as multiplexed immunoassays, monitoring of biowarfare and terrorist agents, and general protein analysis tools.

"CombiMatrix`s intellectual property strategy is designed to provide freedom to operate for CombiMatrix products as well as to establish strong barriers to protect the unique aspects and commercial advantages of our electrochemical synthesis and detection technologies," said Dr. Jeff Oster, Senior Vice President, Legal at CombiMatrix. "In this case, we decided to wait the nine months after publication of the grant to let the opposition period expire before announcing."

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix`s group`s technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 41 patent portfolios, which include over 150 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 19

http://biz.yahoo.com/bw/060316/20060316005227.html?.v=1

[nort.]

Ziel aus den Augen nicht verlieren

[nort.]

Barchart zeigt volles GRÜN

http://quotes.barchart.com/texpert.asp?sym=cbmx

[whyso]

Die zwei hier passen wohl sehr gut zusammen

GN8 Y`all & weiter UP,
Whyso

[whyso]

Watch this space

(@Multicash, deine im Threadtitel genannte "Train" is now gathering speed )

Diagnostic Devices Break Out

Researchers believe 2006 will be a big year, with the number of microarray-based diagnostic devices increasing from just one to several.

Patrick McGee, Senior Editor

Diagnosing disease is an imperfect science in many ways. For example, most tumor classifications are done based on visual characteristics and then confirmed using immunohistochemical tests, but despite these steps, many cases are still difficult to diagnose. When it comes to treating cancer and other diseases and conditions, the
click the image to enlarge

The AmpliChip CYP450 Test predicts phenotype, a factor which influences the concentration of drug in a patient’s blood and allows clinicians to determine therapeutic strategies and optimal dosing for patients. (Source: Roche Diagnostics Corp.)
efficacy and toxicity of drugs vary greatly from person to person, and genetics can account for 20% to 95% of the variability in drug disposition and effects. Microarray-based diagnostic tests are an emerging solution to this quandary because they have the potential to detect diseases and predict the desired and undesired effects of drugs developed to treat them.

In January 2005, the AmpliChip CYP450 Test became the first microarray for in vitro diagnostic use approved by the US Food and Drug Administration (FDA). The AmpliChip, which is manufactured by Roche Diagnostics Corp., Indianapolis, detects variations in CYP2D6 and CYP2C19, two cytochrome P450 genes that play a key role in the metabolism of many drugs, so it can be used to ensure that drugs are used in an optimal manner and to prevent harmful drug interactions. But it is unlikely that the AmpliChip will be the only microarray-based diagnostic for long, researchers in the field say.

"Everyone can see the writing on the wall, that the microarrays are going to be a very, very powerful tool both in the diagnosis and management of disease and on the prognostic side," says David Baunoch, PhD, president and cheif operating officer of CombiMatrix Molecular Diagnostics Inc. (CMD), Irvine, Calif. CMD, a subsidiary of CombiMatrix Corp., Newport Beach, Calif., develops microarray-based diagnostics. "We`re going to see a whole wave of microarray applications that are going to move into the clinical lab in the next decade. The first will be focused on unresolved diagnostic challenges, but I think ultimately what you`re going to see is a wave of tests that are going to revolutionize how we manage patient care on a daily basis." Baunoch adds that diagnostic lymphoma arrays, which are being developed by CMD and several other companies, will likely be the first microarray product approved since the AmpliChip.

Unlimited applications
Walter Koch, PhD, head of research at Roche Molecular Diagnostics, also sees a promising future for microarray-based diagnostics. "We believe that microarrays will be another tool in the toolbox for physicians in the laboratories for molecular diagnostic purposes in the years ahead. The number of applications are basically unlimited in terms of what you can dream up," says Koch. "I believe the initial wave will primarily be in oncology. It just seems to be the disease area where we have a greater in-depth understanding of the genes that are involved that lead to the disease and that also define differential or subclasses of disease which dictate differential treatment regimes. I think there will be more of these. I don`t know that it`s going to be a huge number very quickly. I think it`s going to be incremental."

Glenda Anderson, CEO of PathWork Informatics Inc., San Jose, Calif., says 2006 will be a breakout year for microarray-based diagnostics, and she sees a number of factors behind the development of these new products. One is "significant" improvements in reproducibility for microarrays, reagents, and kits. "They are now demonstrating the kind of performance you`d expect from a clinical product. Three years ago it wasn`t as clear that you could say that. That`s probably the overarching
Last January, the AmpliChip CYP450 Test became the first microarray for in vitro diagnostic use approved by the FDA. It detects variations in CYP2D6 and CYP2C19, two cytochrome P450 genes that play a key role in the metabolism of many drugs. (Source: Roche Diagnostics Corp.)
trend, improved reproducibility," she says. Another factor is the improved performance of scanners and some other ancillary instruments required for diagnostics. Also, because the human genome is more fully characterized, the choice of oligonucleotides or probes bound to arrays are more specific, so there is less cross-hybridization.

Another key factor, Anderson says, is that the technology offered by Affymetrix, Santa Clara, Calif., has stabilized. This is key, because many microarray-based diagnostic platforms are based on their technology. The company has a program called Powered by Affymetrix which enables companies to license their GeneChip technology, the first microarray instrumentation system for molecular diagnostics laboratories. This allows the partner companies to develop microarray products for applications in diagnostics, forensics, animal testing, and more.

One partner is Roche, whose AmpliChip is used on the GeneChip Microarray Instrumentation System. One advantage of the GeneChip platform is a scalability that allows it to be used for investigating specific genetic targets or an entire genome of human, plant, animal, or microbial systems. PathWork Informatics is another program partner, as is BioMérieux, Marcy l`Etoile, France; Vita Genomics, Taipei, Taiwan; and Veridex LLC, a Johnson & Johnson company, Warren, N.J.

Incorporating microarrays
Under their partnership with Affymetrix, PathWork Informatics can incorporate Affymetrix microarrays into the diagnostic PathWork Oncology Suites they are developing. Anderson says PathWork has two in vitro diagnostic kits in development and both comprise proprietary software and a companion microarray that allow a collection of tests to be done on one microarray. When approved, the suites will be sold to clinical laboratories which can use them to process a biopsy specimen and assess multiple parameters.

The first suite will identify a tissue of origin and compare the gene-expression signature and gene-expression data for a specimen against 15 alternative candidate tissues of origin. "In this way, we take a single specimen and answer many questions. Is this specimen similar to a prostate cancer, is it similar to breast cancer, is it similar to a melanoma, is it similar to a lymphoma?" Anderson says. "The second product in development is expected to answer a more clinically diverse mix of questions: How
The CombiMatrix Custom 4x2K Array is predominantly developed for diagnostic applications and allows for the simultaneous analysis of 2000 unique markers for four independent patient samples. (Source: CombiMatrix Molecular Diagnostics Inc.)
aggressive is this tumor, is it resistant to several of the commonly used therapeutics?"

Under the partnership, PathWork will design the products, Affymetrix will manufacture the microarrays, and PathWork will then sell the diagnostic suites. The PathChips, as they are called, will be gene expression mRNA-based tests, as opposed to the AmpliChip, which is a DNA-based test. "The AmpliChip is looking at polymorphism in the nuclear DNA; we`re looking at variations in expression. In fact, we expect to be the first gene expression-based test to find our way into, and with luck, out the other side of the FDA," Anderson says. While PathWork is a small, early-stage company, they have already formed collaborations with many cancer centers across the country, something that accelerated their path to development, she adds.

Roche is working on two near-term cancer applications based on the Affymetrix platform. One is a p53 tumor suppressor re-sequencing array. It uses an approach similar to the AmpliChip, but it is much denser, using more than 220,000 oligonucleotides to determine the sequence of the p53 tumor suppressor gene, which is mutated in over half of all cancers. The second will use gene expression profiling to classify some 20 different types of leukemia and related diseases like myelodysplastic syndrome. The diagnostic will target a subset of a few thousand genes which optimally distinguish and discriminate between different classes of leukemia, Koch says.

Home brew
One company that is not partnering with Affymetrix is CMD, which is instead taking a "home brew" approach to diagnostics. Home brew tests are brought to market by reference laboratories and medical centers and are configured using analyte-specific reagents (ASRs). While the components that comprise home brew tests are regulated by the FDA, especially regarding features such as quality control and labeling of reagents, the agency does not regulate how the tests are put together.

But that could be changing, Anderson says. "If you look at the regulatory landscape today, the FDA is taking a much more active role in restricting access to the market as a home brew, not only for the microarray platforms, but we`re seeing the same in RT-PCR-based tests as well. So even those who have taken an alternative technology platform and offered it up as a home brew using CLIA [Clinical Laboratory Improvement Amendments] as their regulatory framework are finding that the FDA has something to say about it. . . . In summary, what we expect to see is a more consistent position on the FDA`s part in terms of regulating molecular diagnostics independent of the platform."

Baunoch says CMD is focusing on several areas with unresolved diagnostic challenges for its home brew tests. The first is melanoma, specifically a test that could distinguish between a benign dysplastic nevis (a mole) and melanoma. "It`s really the most miscalled of all diagnoses in the pathology world. It`s very difficult. Even the very best dermatopathologists have difficulty in calling these cases. What we were looking for was a test that would allow us to take these moles and determine which ones were actually melanomas so that patients could be treated in the appropriate fashion." Baunoch adds that this is a potentially large market because the number of melanoma cases in the United States has climbed from approximately 40,000 annually just seven years ago to over 60,000 annually today, with 8,000 melanoma-related deaths yearly.

CMD is collaborating with Scott Binder, MD, to develop a gene-based test for the diagnosis of malignant melanoma using routinely prepared formalin-fixed paraffin-embedded material. Binder is in the department of pathology and laboratory medicine at the David Geffen School of Medicine at the University of California, Los Angeles. In addition to collaborating on this project, Binder and his colleagues will provide clinically validated patient samples for the development and validation phase of the project. The test will serve as an adjunct to traditional morphologic and immunohistochemical methods and should be available by the end of the year.

CMD is also developing array-based methods that would enable the development of a molecular classification system for tumors. Today, most tumor classification is done based on visual characteristics. A piece of the tumor is taken, stained with dyes, and examined under a microscope, and then confirmatory immunohistochemical tests are conducted. "Rather than diagnosing it under a microscope we could basically take a very small portion of that tumor, apply it to an array, and diagnose it." CMD first introduced the idea for such a microarray three years ago, and there are now seven or eight companies doing similar work, Baunoch says. He adds that CMD plans to have its tumor classification system on the market early in 2007.

http://www.dddmag.com/showpr.aspx?PUBCODE=016&ACCT=160000010…

[whyso]

[posting]20.739.968 von nort. am 16.03.06 18:38:39[/posting]Nort, my main man ...gute Reise

Gestern Abend drüben:
CBMX Last: 2.59 Change: +0.23 +10.95% Volume: 2,552,399 4:00pm 3/21/2006

[nort.]

[posting]20.900.877 von whyso am 22.03.06 08:40:18[/posting]Hi whyso,

heute in USA Today gesehen Perfekt, absoluter perfekter Rebout, Chart, Volumen und Story.

Schön, wenn man sich über Dezember supergünstig eindecken konnte

nort

[MultiCash]

Hallo Freunde,
ein warmer Geldregen im kalten März kommt uns doch gut gelegen, gelle?

[nort.]

Barchart steht auf vollem grün. Grüner geht es nicht mehr

http://quotes.barchart.com/texpert.asp?sym=cbmx

[whyso]

Antwort auf Beitrag Nr.: 20.941.352 von nort. am 24.03.06 17:51:18

CBMX wird bald wieder ein 10$ stock sein...die Trennung läuft auf Volldampf voraus

Schaut Euch der IR Name hinter die letzten 2 "ad hocs" von Acacia mittlerweile an, nicht mehr der hier:

Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: [phone]

sondern jetzt der ehemalige Ehemann von Frau Hunter & "Whiskystimme Sänger":

Acacia Research Corporation
Rob Stewart (Investor Relations), 949-480-8300
Fax: [phone]

Naja, Rob & Rod Stewart ist fast das selber ...oder?

Die Trennung wird langsam aber sicher vollzogen!

Ich freue mich wirklich sehr auf die kommende "eigenständigkeit" des CBMX,
Whyso

[whyso]

Da haben wir unsere "W"-wie WINNER...



Die anteile bleiben bei mir festgenagelt im Depot,
Steigende Grüße,
Whyso

P.S. man trifft sich (ganz beiläufig) im Indien dieser Woche...

[whyso]

Digitalised DNA -(Dr Andy o' Shea)-...fürs Volk:
http://www.combimatrix.com/docs/710KiroSpotlight_032906.mp3

Wir stehen hier am Anfang!
Whyso

[ichwillsjetztwissen]

Was ist mit den License Agreements mit Sony und Fujitsu?
Wenn man sich den Kurs anschaut, geht das ja schon in Richtung "None Event"
Die Meldungen kamen doch am Freitag noch zur Börsenzeit.

[whyso]

Watch this space...

http://www.fda.gov/OHRMS/DOCKETS/98fr/E6-5203.htm

[whyso]

CNBC am 17 May ...three workdays and counting

Rodman & Renshaw trommeln für CBMX ab Montag
(wer errinert sich hier am der NVAX Entwicklung kurz nach der R&R Analyse???)

Schönes Wochenende ihr lieben,
Whyso

[whyso]

WOW...jetzt bin ich echt gespannt auf das Interview mit Kumar am Abend auf der "Squak Box"

"The US government continues to be justifiably concerned about the entrance of highly pathogenic avian influenza into North America, and CombiMatrix continues to demonstrate the power of its technology in this realm," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "This collaboration with EAI gets our technology into the field and into the hands of people and groups standing watch on US soil. This program is in addition to our participation in the US Government\'s National Early Detection System."

"We are pleased that the Institute for Defense and Homeland Security has agreed to fund this combined effort with CombiMatrix," said Dr. Joe Dudley, Chief Scientist at EAI. "We believe that the CombiMatrix system is a powerful, versatile, and portable system for influenza monitoring. We believe that this approach, combined with EAI\'s mobile-laboratory products and expertise, will provide a very powerful tool for monitoring and preparedness in the event of a pandemic."


Watch this space:



Good trades but steady hands mit CBMX,
Whyso

[whyso]

CBMX Lesenswertes...

Why Brean Murray thinks CBMX=12 PT 1
by: barbing1965 05/22/06 01:25 pm
Msg: 35406 of 35432

CombiMatrix group:

* In January 2006, the CombiMatrix group launched a series of catalog microarrays specifically designed for microRNA analysis. MicroRNAs ("miRNAs") are small, RNA molecules encoded in the genomes of plants and animals. These highly conserved, approximately 21-mer RNAs regulate the expression of genes and are believed to be critical to controlling physiology in areas that include neural development, viral disease, and cancer. Each miRNA is thought to regulate multiple genes, and since hundreds of miRNA genes are predicted to be present in higher eukaryotes the potential regulatory circuitry afforded by miRNAs is enormous. There is evidence that miRNAs may act as key regulators of processes as diverse as early development, cell proliferation and cell death, apoptosis and fat metabolism, and cell differentiation.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of Colorado Health Sciences Center under the Company's CombiCore(TM) access program. Under this agreement all University of Colorado researchers can purchase, through their microarray core facility, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the University of Colorado Health Science Center Microarray Core Facility.
* In January 2006, the CombiMatrix group entered into a non-exclusive distribution agreement with Cold Spring Biotech to distribute CombiMatrix products and services in mainland China, Taiwan, and Hong Kong. Under the terms of the agreement, Cold Spring Biotech will market and sell CustomArrays(TM) and CatalogArrays(TM), including the recently introduced Influenza A Research Microarray.
* In January 2006, the CombiMatrix group signed a non-exclusive agreement with The University of California Davis under the Company's CombiCore(TM) access program. Under this agreement all University of California Davis researchers can purchase, through the UC Davis Genome Center, CombiMatrix' CustomArrays(TM) and CatalogArrays(TM), including array processing services performed at the UC Davis Genome Center.
* In January 2006, the CombiMatrix group expanded its relationship with its existing partner, INBIO, for the Asia Pacific region. Major components of the expanded relationship include the transfer of day-to-day operational responsibility and majority ownership of CombiMatrix Corporation's wholly owned subsidiary, CombiMatrix K.K. (the "KK") to INBIO along with an expanded distribution agreement that encompasses Japan. INBIO obtained 67% of the voting interests in the KK and expanded its distribution agreements with the CombiMatrix group. INBIO assumed all operational and financial responsibilities of the KK including its liabilities.
* In January 2006, the CombiMatrix group announced that the 2006 U.S. Defense Appropriations Bill signed by President Bush included an allocation of $2.4 million to fund efforts by the CombiMatrix group to further develop its microarray technologies for the detection of biological and chemical threat agents.
* In February 2006, the CombiMatrix group began work on its one-year, $2.1 million contract with the US Department of Defense ("DoD"). Funding for this contract, which focuses on the use of CombiMatrix' array technology for military and antiterrorist applications, was previously announced as part of the DoD budget. CombiMatrix's development program with the DoD is focused on the integration of CombiMatrix's biotechnology with microelectronics and microfluidics and the development of an automated system with maximum flexibility and sensitivity for biothreat agents with reduced size and cost.

[whyso]

"Despite the cluster of deaths, the virus has not mutated into a form easily passed among humans, experts said. Scientists have seen examples of bird flu passing between blood relatives in a handful of smaller cases, leading to speculation of a possiblegenetic vulnerability."
http://www.thejakartapost.com/detaillgen.asp?fileid=20060528…

und wie will man dieses überhaupt feststellen in die nächste Zukunft????

Enter CBMX mit sein 4std Microarray,
Whyso

[whyso]

Ab jetzt wird es richtig Spannend mit CBMX:::::




Very good news for CBMX



Alpha Innotech and CombiMatrix Diagnostics Combine Products in a Marketing Agreement

SAN LEANDRO, Calif.--(BUSINESS WIRE)--June 15, 2006--Alpha Innotech Corp. (OTCBB:APNO - News), a leading provider of bioanalytical systems for drug discovery and life science research, today announced a marketing agreement with CombiMatrix Molecular Diagnostics (CMDX) to mutually promote and distribute an integrated analysis solution for Comparative Genomic Hybridization. The agreement is centered on the synergies between Alpha Innotech's AlphaScan® laser scanner and CMDX's Comparative Genomic Hybridization (CGH) arrays for neonatal screening and biomarker discovery. As part of the deal, CombiMatrix Molecular Diagnostics will integrate Alpha Innotech's AlphaScan® scanner into its CGH platform. Financial terms were not disclosed.

Sia Ghazvini, Vice President of Business Development at Alpha Innotech, said "We are pleased to be working with CombiMatrix Molecular Diagnostics to provide this integrated solution for customers performing CGH analysis. We believe customers will appreciate a turnkey solution that combines DNA content, a reader, analysis software, and a validated laboratory protocol into a single integrated package. We intend to continue partnering with leading application developers like CMDX to provide best-of-class, application-focused integrated solutions for their customers."

"Our customers are looking for a single integrated platform that will enable them to quickly set up a CGH laboratory and begin running experiments," said Matt Watson, CEO of CMDX. "Alpha Innotech's AlphaScan® scanner represents a key component of that platform and we are excited to be able to offer it as part of our turnkey solution."

http://biz.yahoo.com/bw/060615/20060615005770.html?.v=1


Das könnte so ein Art "Initialzündung" (Neue Finanzierungsnews Inklusiv) mit sich bringen!

Steady hands & deep breath für 06/07,
Whyso